CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Breyanzi (lisocabtagene maraleucel), ...
Imbruvica (Ibrutinib) revolutionized CLL and SLL treatment, with its development journey detailed in Nathan Vardi's book. The drug's creation involved collaboration among investors, scientists, and ...
The National Comprehensive Cancer Network recommendations come as the FDA weighs an indication in chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) for zanubrutinib. As drugmaker ...
No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and ...
About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...
Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk ...
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...
(RTTNews) - Eli Lilly and Co. (LLY) announced that the FDA has expanded cancer med Jaypirca's approval to include treatment for adults with relapsed or refractory chronic lymphocytic leukemia or small ...
In B-CLL, time to first treatment is dependant on the IgVH gene mutations and expression of CD38 on leukemic cells This is an ASCO Meeting Abstract from the 2005 ASCO Annual Meeting. This abstract ...
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results